2025 Q4 -tulosraportti
58 päivää sitten
‧49 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 222 | - | - | ||
| 44 363 | - | - | ||
| 6 145 | - | - | ||
| 93 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 303 362 | 303 362 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 303 362 | 303 362 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sitten · MuokattuAsked AI a bit. Got nothing new about the 50 states.. Other than it's probably April - May based on Immunovia's previous talk. It matches the 8-month "sweet spot". Quote: "the NYSDOH review process frequently takes 6–12 months longer than other states." Other aspects worth considering for the next stock price direction are that it could be extra favorable if it coincides with Immunovia's annual general meeting on Wednesday, May 13. But if it's not ready yet, Immunovia needs to keep its cards close to its chest because marketing for New York will set the validation process back, as marketing is strictly forbidden. Other aspects worth noting about it are, quote: "The Psychological 50: Being "Available in all 50 states" allows the company to stop qualifying its marketing. It simplifies the pitch to large national healthcare networks (like Kaiser Permanente or UnitedHealth), who generally won't partner with a lab that can't serve their New York members." "New York Direct-Pay: New York has a massive population of high-net-worth individuals who utilize "concierge medicine." These patients are often willing to pay the $750 - $995 out-of-pocket price while waiting for insurance. Opening New York unlocks this lucrative "cash-pay" segment immediately." "The Synergy: New York approval actually helps the Medicare case. When a company applies for a National Coverage Determination (NCD), having a "clean" 50-state regulatory record prevents administrative delays."- ·9 t sittenPity. But one can probably expect lower daily stock turnover again if the downturn continues in "this way". Now there must surely be some really good news coming soon, right?!!???
- ·2 päivää sitten · Muokattuhttps://forum.placera.se/inlagg/52bd8c37-e0eb-4446-a382-8e8fc5d87a80 49 out of 50 states I think it's a bit strange that there was some optimism about New York approval a few days ago. But it has disappeared? It should soon be very close to that event. If one can believe Jeff Borcherding's Q4 optimistic afternoon webcast
- ·16.4. · MuokattuIs there any source for Adob's claim, or is it just "fluff"? https://forum.placera.se/inlagg/c3b44de5-91bc-4a3a-8c83-92e3f7116c98 Quotes: "Adob > Immunovia 1 hour ago They seem to be in full swing to secure a strategic partner to increase growth EXTREMELY IMPORTANT but they should easily find a partner" "Adob Abbot or Roche would fit well" https://forum.placera.se/inlagg/c3b44de5-91bc-4a3a-8c83-92e3f7116c98
·16.4. · MuokattuThe risk as I see it is that the wolves in the American financial world are smart enough to wait until Immunovia's cash runs out. Then, when they have the knife to their throat, the wolves can "eat up Immunovia" or buy up the company and their patents for a pittance.·16.4.There is always a risk in a price/demand system. I hope that the management of Immunovia are decent and do not facilitate fraud around corporate actions. - ·15.4.Interesting volume these days. It might seem like "the cork is coming loose" somewhat with the trading. Could it be that people who want out are getting out and people who want in are positioning themselves for some eventual positive changes?·16.4. · MuokattuImmunovia has expressed a clear need for a strategic partner to scale up the commercialization of its new test, PancreaSure, especially in the American market. Here are the types of companies most likely to be partners or future buyers, based on the market's leading players and Immunovia's current strategy: 1. Global diagnostics giants These companies already have the infrastructure and sales force to quickly roll out a test globally. Thermo Fisher Scientific: A world leader in diagnostics that already offers advanced tools for early cancer detection Roche: Dominates the market for liquid biopsies (liquid biopsy) and conducts extensive clinical studies in pancreatic cancer Illumina / Grail: Illumina focuses on next-generation sequencing (NGS) and previously bought Grail for 8 billion dollars to strengthen its position in early cancer detection Siemens Healthineers & GE HealthCare: Leaders in imaging diagnostics (MRI/CT), but are increasingly looking for complementary blood-based tests to offer comprehensive solutions 2. Specialized oncology companies Companies that focus specifically on precision medicine and cancer monitoring. Guardant Health: A direct competitor but also a possible partner, as they lead the development of liquid biopsies for early detection Myriad Genetics: Focuses on genetic risk factors and biomarkers for cancer, which fits well with Immunovia's target group of high-risk patients Exact Sciences: Known for its Cologuard test; they have shown great interest in expanding their portfolio with more tests for early detection of hard-to-treat cancers.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
58 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sitten · MuokattuAsked AI a bit. Got nothing new about the 50 states.. Other than it's probably April - May based on Immunovia's previous talk. It matches the 8-month "sweet spot". Quote: "the NYSDOH review process frequently takes 6–12 months longer than other states." Other aspects worth considering for the next stock price direction are that it could be extra favorable if it coincides with Immunovia's annual general meeting on Wednesday, May 13. But if it's not ready yet, Immunovia needs to keep its cards close to its chest because marketing for New York will set the validation process back, as marketing is strictly forbidden. Other aspects worth noting about it are, quote: "The Psychological 50: Being "Available in all 50 states" allows the company to stop qualifying its marketing. It simplifies the pitch to large national healthcare networks (like Kaiser Permanente or UnitedHealth), who generally won't partner with a lab that can't serve their New York members." "New York Direct-Pay: New York has a massive population of high-net-worth individuals who utilize "concierge medicine." These patients are often willing to pay the $750 - $995 out-of-pocket price while waiting for insurance. Opening New York unlocks this lucrative "cash-pay" segment immediately." "The Synergy: New York approval actually helps the Medicare case. When a company applies for a National Coverage Determination (NCD), having a "clean" 50-state regulatory record prevents administrative delays."
- ·9 t sittenPity. But one can probably expect lower daily stock turnover again if the downturn continues in "this way". Now there must surely be some really good news coming soon, right?!!???
- ·2 päivää sitten · Muokattuhttps://forum.placera.se/inlagg/52bd8c37-e0eb-4446-a382-8e8fc5d87a80 49 out of 50 states I think it's a bit strange that there was some optimism about New York approval a few days ago. But it has disappeared? It should soon be very close to that event. If one can believe Jeff Borcherding's Q4 optimistic afternoon webcast
- ·16.4. · MuokattuIs there any source for Adob's claim, or is it just "fluff"? https://forum.placera.se/inlagg/c3b44de5-91bc-4a3a-8c83-92e3f7116c98 Quotes: "Adob > Immunovia 1 hour ago They seem to be in full swing to secure a strategic partner to increase growth EXTREMELY IMPORTANT but they should easily find a partner" "Adob Abbot or Roche would fit well" https://forum.placera.se/inlagg/c3b44de5-91bc-4a3a-8c83-92e3f7116c98·16.4. · MuokattuThe risk as I see it is that the wolves in the American financial world are smart enough to wait until Immunovia's cash runs out. Then, when they have the knife to their throat, the wolves can "eat up Immunovia" or buy up the company and their patents for a pittance.·16.4.There is always a risk in a price/demand system. I hope that the management of Immunovia are decent and do not facilitate fraud around corporate actions.
- ·15.4.Interesting volume these days. It might seem like "the cork is coming loose" somewhat with the trading. Could it be that people who want out are getting out and people who want in are positioning themselves for some eventual positive changes?·16.4. · MuokattuImmunovia has expressed a clear need for a strategic partner to scale up the commercialization of its new test, PancreaSure, especially in the American market. Here are the types of companies most likely to be partners or future buyers, based on the market's leading players and Immunovia's current strategy: 1. Global diagnostics giants These companies already have the infrastructure and sales force to quickly roll out a test globally. Thermo Fisher Scientific: A world leader in diagnostics that already offers advanced tools for early cancer detection Roche: Dominates the market for liquid biopsies (liquid biopsy) and conducts extensive clinical studies in pancreatic cancer Illumina / Grail: Illumina focuses on next-generation sequencing (NGS) and previously bought Grail for 8 billion dollars to strengthen its position in early cancer detection Siemens Healthineers & GE HealthCare: Leaders in imaging diagnostics (MRI/CT), but are increasingly looking for complementary blood-based tests to offer comprehensive solutions 2. Specialized oncology companies Companies that focus specifically on precision medicine and cancer monitoring. Guardant Health: A direct competitor but also a possible partner, as they lead the development of liquid biopsies for early detection Myriad Genetics: Focuses on genetic risk factors and biomarkers for cancer, which fits well with Immunovia's target group of high-risk patients Exact Sciences: Known for its Cologuard test; they have shown great interest in expanding their portfolio with more tests for early detection of hard-to-treat cancers.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 222 | - | - | ||
| 44 363 | - | - | ||
| 6 145 | - | - | ||
| 93 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 303 362 | 303 362 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 303 362 | 303 362 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
2025 Q4 -tulosraportti
58 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sitten · MuokattuAsked AI a bit. Got nothing new about the 50 states.. Other than it's probably April - May based on Immunovia's previous talk. It matches the 8-month "sweet spot". Quote: "the NYSDOH review process frequently takes 6–12 months longer than other states." Other aspects worth considering for the next stock price direction are that it could be extra favorable if it coincides with Immunovia's annual general meeting on Wednesday, May 13. But if it's not ready yet, Immunovia needs to keep its cards close to its chest because marketing for New York will set the validation process back, as marketing is strictly forbidden. Other aspects worth noting about it are, quote: "The Psychological 50: Being "Available in all 50 states" allows the company to stop qualifying its marketing. It simplifies the pitch to large national healthcare networks (like Kaiser Permanente or UnitedHealth), who generally won't partner with a lab that can't serve their New York members." "New York Direct-Pay: New York has a massive population of high-net-worth individuals who utilize "concierge medicine." These patients are often willing to pay the $750 - $995 out-of-pocket price while waiting for insurance. Opening New York unlocks this lucrative "cash-pay" segment immediately." "The Synergy: New York approval actually helps the Medicare case. When a company applies for a National Coverage Determination (NCD), having a "clean" 50-state regulatory record prevents administrative delays."
- ·9 t sittenPity. But one can probably expect lower daily stock turnover again if the downturn continues in "this way". Now there must surely be some really good news coming soon, right?!!???
- ·2 päivää sitten · Muokattuhttps://forum.placera.se/inlagg/52bd8c37-e0eb-4446-a382-8e8fc5d87a80 49 out of 50 states I think it's a bit strange that there was some optimism about New York approval a few days ago. But it has disappeared? It should soon be very close to that event. If one can believe Jeff Borcherding's Q4 optimistic afternoon webcast
- ·16.4. · MuokattuIs there any source for Adob's claim, or is it just "fluff"? https://forum.placera.se/inlagg/c3b44de5-91bc-4a3a-8c83-92e3f7116c98 Quotes: "Adob > Immunovia 1 hour ago They seem to be in full swing to secure a strategic partner to increase growth EXTREMELY IMPORTANT but they should easily find a partner" "Adob Abbot or Roche would fit well" https://forum.placera.se/inlagg/c3b44de5-91bc-4a3a-8c83-92e3f7116c98·16.4. · MuokattuThe risk as I see it is that the wolves in the American financial world are smart enough to wait until Immunovia's cash runs out. Then, when they have the knife to their throat, the wolves can "eat up Immunovia" or buy up the company and their patents for a pittance.·16.4.There is always a risk in a price/demand system. I hope that the management of Immunovia are decent and do not facilitate fraud around corporate actions.
- ·15.4.Interesting volume these days. It might seem like "the cork is coming loose" somewhat with the trading. Could it be that people who want out are getting out and people who want in are positioning themselves for some eventual positive changes?·16.4. · MuokattuImmunovia has expressed a clear need for a strategic partner to scale up the commercialization of its new test, PancreaSure, especially in the American market. Here are the types of companies most likely to be partners or future buyers, based on the market's leading players and Immunovia's current strategy: 1. Global diagnostics giants These companies already have the infrastructure and sales force to quickly roll out a test globally. Thermo Fisher Scientific: A world leader in diagnostics that already offers advanced tools for early cancer detection Roche: Dominates the market for liquid biopsies (liquid biopsy) and conducts extensive clinical studies in pancreatic cancer Illumina / Grail: Illumina focuses on next-generation sequencing (NGS) and previously bought Grail for 8 billion dollars to strengthen its position in early cancer detection Siemens Healthineers & GE HealthCare: Leaders in imaging diagnostics (MRI/CT), but are increasingly looking for complementary blood-based tests to offer comprehensive solutions 2. Specialized oncology companies Companies that focus specifically on precision medicine and cancer monitoring. Guardant Health: A direct competitor but also a possible partner, as they lead the development of liquid biopsies for early detection Myriad Genetics: Focuses on genetic risk factors and biomarkers for cancer, which fits well with Immunovia's target group of high-risk patients Exact Sciences: Known for its Cologuard test; they have shown great interest in expanding their portfolio with more tests for early detection of hard-to-treat cancers.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 222 | - | - | ||
| 44 363 | - | - | ||
| 6 145 | - | - | ||
| 93 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 303 362 | 303 362 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 303 362 | 303 362 | 0 | 0 |